Cataract incision size is just right thanks to new technology

Article

Incision sizes needed to remove cataracts have been significantly reduced by new technology, such as the vision enhancement system (Stellaris; Bausch & Lomb) which allows surgeons to make two 1.8 mm cuts on either side of the eye.

Incision sizes needed to remove cataracts have been significantly reduced by new technology, such as the vision enhancement system (Stellaris; Bausch & Lomb) which allows surgeons to make two 1.8 mm cuts on either side of the eye.

Now that the device has been used as part of clinical trials in a number of hospitals it is being sold to NHS trusts in the UK for £70,000 (around €92,000). The machine guides surgeons to make the right incisions, and the clouded lens is broken up using ultrasound before it is extracted. A new folded lens is injected into the space, where it is unfurled.

"It's a very quick and efficient procedure, it's painless, [with] no stitches, and [patients] can get up and walk out straight afterwards without the need for a patch and little danger of infection," said Sheraz Daya, MD, a consultant ophthalmologist at Queen Victoria Hospital, West Sussex, UK.

Other consultants agreed with Dr Daya's assessment, although they stressed that Stellaris was not the only device capable of reducing the incision to 1.8 mm. At least two other phaco systems (Sovereign; Advanced Medical Optics & Infiniti; Alcon Laboratories) are available.

"All these technologies are a move in the right direction," said Larry Benjamin, DO, an eye surgeon at Stoke Mandeville Hospital, Buckinghamshire, UK. "Smaller cuts are better, while the mechanism keeps the eye steady. The only problem is many of the lenses on the market aren't yet small enough to fit through this kind of incision, so one side of the technology has yet to catch up with the other."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.